GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Net Change in Cash

Nexalin Technology (Nexalin Technology) Net Change in Cash : $0.37 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Nexalin Technology's Net Change in Cash for the three months ended in Mar. 2024 was $-0.03 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $0.37 Mil.

Nexalin Technology Net Change in Cash Historical Data

The historical data trend for Nexalin Technology's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Net Change in Cash Chart

Nexalin Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Change in Cash
0.02 0.58 -0.50 0.42

Nexalin Technology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.06 0.13 0.22 -0.03

Nexalin Technology Net Change in Cash Calculation

Nexalin Technology's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.835+4.453+-0.2+0
=0.42

Nexalin Technology's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.763+0.729+0+0
=-0.03

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalin Technology Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology (Nexalin Technology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Net Change in Cash
Comparable Companies
DYNT CMXC MHTX HSCS MOTS TNON SINT TIVC VYCO VTAK ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Website
https://www.nexalin.com
Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.
Executives
Marilyn Elson 10 percent owner, officer: Ms. Elson serves as CFO 32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad director 6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White director, officer: President/CEO 1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens director, officer: Chief Medical Officer 4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden director 3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser other: Spouse
Ben Hu director 7021 EDGERTON ROAD, NORTH ROYALTON OH 44133

Nexalin Technology (Nexalin Technology) Headlines

From GuruFocus

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

By Value_Insider Value_Insider • 11-14-2022

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures

By Marketwired • 10-16-2023

Nexalin Technology Provides 2022 Year-End Business Update

By sperokesalga sperokesalga • 03-27-2023

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

By Marketwired • 07-26-2023

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

By Stock market mentor Stock market mentor • 01-24-2023

Nexalin Technology CEO Provides Letter to Shareholders

By Stock market mentor Stock market mentor • 01-05-2023

Nexalin's CEO Mark White to be Interviewed Live on �The Big Biz Show� Today at 3PM Eastern Time

By Marketwired • 08-03-2023

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

By Marketwired • 08-07-2023

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's tACS Devices in the Asia Pacific Region

By sperokesalga sperokesalga • 06-01-2023

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

By Marketwired • 07-10-2023